Champions Oncology (CSBR) investor relations material

Executive summary

• Revenue for Q1 fiscal 2027 was $15.2 million, up 8.8% year-over-year, driven by higher pharmacology services and data license revenue.

• Gross margin improved to 50% from 43% in the prior year quarter, with oncology services margin rising to 51%.

• Adjusted EBITDA reached $671,000, marking the fifth consecutive quarter of positive adjusted EBITDA.

• Net loss narrowed to $426,000, including $1.1 million in non-cash expenses, improved from $466,000 in the prior year.

• Continued investment in commercial expansion, research, and data platform initiatives, particularly in the Corellia subsidiary.

Financial highlights

• Translational oncology services generated $14.3 million in revenue, with margins holding steady.

• Data licensing revenue was $893,000, exceeding all of fiscal 2026 in a single quarter.

• Cost of oncology revenue decreased 5.8% to $7.5 million.

• Sales and marketing expense rose 66.6% to $3.1 million, reflecting commercial team expansion.

• General and administrative expense was $2.7 million, up 4.0% year-over-year.

Outlook and guidance

• Management expects continued revenue growth and profitability expansion, focusing on leveraging investments made in fiscal 2026.

• Revenue conversion rates from contracted studies remain strong, and the pipeline is robust.

• Cash on hand and expected cash flows are considered adequate to fund operations through at least September 2027.

• Strategic focus remains on data initiatives and potential redeployment of resources from Corellia if external funding is secured.

• Continued investment in radiopharmaceutical capabilities and target discovery initiatives.